Table 2.

Univariate analysis of the association between clinical and pathologic characteristics, mutations of PIK3CA, and loss of PTEN in 110 mCRC patients treated with anti-EGFR monoclonal antibodies panitumumab or cetuximab

PIK3CAKRASPIK3CA and/or KRASPTEN
WT (%)Mut (%)PWT (%)Mut (%)PWT (%)Mut (%)PNormal (%)Loss (%)P
Sex
    Men58 (81.7)13 (18.3)0.08055 (77.5)16 (22.5)0.04643 (60.6)28 (39.4)0.68431 (63.3)18 (36.7)0.643
    Women37 (94.8)2 (5.13)22 (57.9)16 (42.1)21 (55.3)17 (44.7)18 (56.2)14 (43.8)
Age (y)
    ≤6554 (87.1)8 (12.9)1.00045 (72.6)17 (27.4)0.62138 (61.3)24 (38.7)0.66425 (55.6)20 (44.4)0.548
    66–7424 (85.7)4 (14.3)17 (63.0)10 (37.0)14 (51.8)13 (48.2)13 (61.9)8 (38.1)
    ≥7517 (89.5)2 (10.5)14 (73.7)5 (26.3)12 (63.2)7 (36.8)10 (71.4)4 (28.6)
Site of T *
    Colon48 (69.6)21 (30.4)0.31962 (89.9)7 (10.1)0.15741 (59.4)28 (40.6)0.15330 (58.8)21 (41.2)0.715
    Sigma-rectum10 (90.9)1 (9.1)10 (90.9)1 (9.1)9 (81.8)2 (18.2)5 (71.4)2 (28.6)
    Rectum18 (66.7)9 (33.3)21 (75.0)7 (25.0)13 (48.1)14 (51.9)14 (66.7)7 (33.3)
Cutaneous rash
    0–149 (67.1)24 (32.9)0.49462 (83.8)12 (16.2)0.54538 (52.0)35 (48.0)0.13632 (55.2)26 (44.8)0.064
    2–324 (75.0)8 (25.0)29 (90.6)3 (9.4)22 (68.7)10 (31.3)16 (80.0)4 (20.0)
  • Abbreviations: WT, wild-type; Mut, mutated.

  • * In one case, primary site was small bowel, and in one case, primary tumor sites were multiple (colon and rectum; P values measured by Fisher's exact test).